↓ Skip to main content

When is dual bronchodilation indicated in COPD?

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, August 2017
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (70th percentile)
  • Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

twitter
8 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
18 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
When is dual bronchodilation indicated in COPD?
Published in
International Journal of Chronic Obstructive Pulmonary Disease, August 2017
DOI 10.2147/copd.s138554
Pubmed ID
Authors

Mike Thomas, David MG Halpin, Marc Miravitlles

Abstract

Inhaled bronchodilator medications are central to the management of COPD and are frequently given on a regular basis to prevent or reduce symptoms. While short-acting bronchodilators are a treatment option for people with relatively few COPD symptoms and at low risk of exacerbations, for the majority of patients with significant breathlessness at the time of diagnosis, long-acting bronchodilators may be required. Dual bronchodilation with a long-acting β2-agonist and long-acting muscarinic antagonist may be more effective treatment for some of these patients, with the aim of improving symptoms. This combination may also reduce the rate of exacerbations compared with a bronchodilator-inhaled corticosteroid combination in those with a history of exacerbations. However, there is currently a lack of guidance on clinical indicators suggesting which patients should step up from mono- to dual bronchodilation. In this article, we discuss a number of clinical indicators that could prompt a patient and physician to consider treatment escalation, while being mindful of the need to avoid unnecessary polypharmacy. These indicators include insufficient symptomatic response, a sustained increased requirement for rescue medication, suboptimal 24-hour symptom control, deteriorating symptoms, the occurrence of exacerbations, COPD-related hospitalization, and reductions in lung function. Future research is required to provide a better understanding of the optimal timing and benefits of treatment escalation and to identify the appropriate tools to inform this decision.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 18 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 18 100%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 5 28%
Other 3 17%
Student > Ph. D. Student 3 17%
Professor 2 11%
Student > Bachelor 1 6%
Other 3 17%
Unknown 1 6%
Readers by discipline Count As %
Medicine and Dentistry 9 50%
Pharmacology, Toxicology and Pharmaceutical Science 4 22%
Psychology 2 11%
Social Sciences 1 6%
Nursing and Health Professions 1 6%
Other 0 0%
Unknown 1 6%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 October 2017.
All research outputs
#3,856,797
of 14,995,047 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#473
of 1,797 outputs
Outputs of similar age
#79,443
of 271,250 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#18
of 56 outputs
Altmetric has tracked 14,995,047 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 1,797 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 271,250 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 56 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.